Latest: Watch here for details of new products and services.
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
News of the day
Dragon Sells EPO Business; Focus on Antibiotic Core Business
November 14, 2008--Dragon Pharmaceutical Inc. (TSX: DDD; OTCBB: DRUG; BBSE: DRP) today announced that it has entered an agreement with an unaffiliated party for the sale of its EPO business which accounted for less than 3% of Dragon's consolidated revenue for the first nine months of 2007. The decision was made based on the studies of the EPO market which showed limited growth potential, if not downward trend, during the next three years. The Company considers this decision an important part of... moreDragon Achieved Solid Increase in Sales and Profits from Continuing Operations for Q3
November 14, 2008--Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG; BBSE: DRP) today announced its financial results for the three and nine months ended September 30, 2007, showing strong growth in sales and profits for its core antibiotic business. Meanwhile, the Company also announced the sale of its EPO operation to an unaffiliated party through a separate press release. moreBoehringer Ingelheim to sign cooperation with HISOAR in China
Taizhou/China and Ingelheim/Germany, 28 August 2008 - Boehringer Ingelheim and Hisoar, a Chinese pharmaceutical production company based in Taizhou, today jointly announced a strategic production alliance in China. Within the the framework of this production alliance Boehringer Ingelheim complements its worldwide chemical production network with strong partners for the manufacturing of chemical intermediates for its active pharmaceutical ingredients (APIs). These chemicals will then be... moreIndustry news search
Most Viewed News
- Dragon Sells EPO Business; Focus on Antibiotic Core Business
- Dragon Achieved Solid Increase in Sales and Profits from Continuing Operations for Q3
- AtheroGenics Reports Positive Results From ANDES Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes
- ProStrakan and Orexo Extend Licensing Agreement for Rapinyl/Abstral to include North America
- CYTOMEDIX RETAINS DR. DAVID F. COUNTS, INVENTOR OF COMPANY'S ANTI-INFLAMMATORY PEPTIDE PATENT
- RSS Feed...
Latest news by category
Development
- Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
- Memory Pharmaceuticals Closes Final Tranche of Equity Financing with The Stanley Medical Research Institute
- Randomized Phase 2 Study of IMC-A12 and IMC-1121B for Advanced Prostate Cancer Commences Patient Enrollment
- More news...
Company releases
- Half of surveyed physicians expect to replace between 6 percent and 15 percent of their Sustiva prescriptions with Isentress
- BAXTER ANNOUNCES LICENSING AGREEMENT FOR INNOCOLL’S GENTAMICIN SURGICAL IMPLANT IN THE UNITED STATES
- PharmiGene receives regulatory approval for test assessing risk of adverse drug reaction to Carbamazepine
- More news...
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us